Check for updates

OPEN ACCESS

EDITED BY Michele Lanza, University of Campania Luigi Vanvitelli, Italy

REVIEWED BY Virgilio Galvis, Centro Oftalmológico Virgilio Galvis, Colombia Majid Moshirfar, John A. Moran Eye Center, College of Health, University of Utah, United States

*CORRESPONDENCE Yueguo Chen ⊠ chenyueguo@263.net

RECEIVED 22 May 2024 ACCEPTED 02 August 2024 PUBLISHED 12 August 2024

CITATION

Dai Z, Liu Z, Zhang Y, Yuan Y, Liu Y, Wang Y, Yu S and Chen Y (2024) Topography-guided photorefractive keratectomy combined with accelerated corneal collagen cross-linking versus cross-linking alone for progressive keratoconus: a long-term prospective cohort study.

Front. Med. 11:1420264. doi: 10.3389/fmed.2024.1420264

COPYRIGHT

© 2024 Dai, Liu, Zhang, Yuan, Liu, Wang, Yu and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Topography-guided photorefractive keratectomy combined with accelerated corneal collagen cross-linking versus cross-linking alone for progressive keratoconus: a long-term prospective cohort study

Zhihao Dai^{1,2,3}, Ziyuan Liu^{1,2,3}, Yu Zhang^{1,2,3}, Yufei Yuan^{1,2,3}, Yan Liu^{1,2,3}, Yuexin Wang^{1,2,3}, Shuo Yu^{1,2,3} and Yueguo Chen^{1,2,3}*

¹Department of Ophthalmology, Peking University Third Hospital, Beijing, China, ²Beijing Key Laboratory of Restoration of Damaged Ocular Nerve, Peking University Third Hospital, Beijing, China, ³Peking University Institute of Laser Medicine, Beijing, China

Purpose: To comprehensively compare the long-term outcome of the combined topography guided photorefractive keratectomy (TG-PRK) with accelerated corneal cross-linking (ACXL) and ACXL alone in eyes with progressive keratoconus. The analysis focused on the changes in the detailed corneal aberrometric values.

Methods: This single-center, prospective cohort study included 28 patients (30 eyes) of the TG-PRK plus ACXL group and 14 patients (15 eyes) of the ACXL alone group. The mean duration of the follow-up was 44 ± 10.18 months (ranged from 31 to 65 months). The preoperative data and the postoperative measurement data at the last follow-up visit, including demographic data, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction, corneal topography, pachymetry, aberrometry and densitometry were analyzed.

Results: The CDVA significantly improved in the TG-PRK plus ACXL group at the last follow-up visit (p = 0.006), while no significant improvement was found in the ACXL alone group (p = 0.432). The maximal keratometry of the anterior corneal surface (Kmax) of both groups significantly decreased at the last follow-up visit (p < 0.05). Compared with the ACXL alone group, the Kmax of the TG-PRK plus ACXL group showed a greater decline (p = 0.008). The total corneal aberrations, the corneal lower-order aberrations (LOAs), the corneal higher order aberrations (HOAs), the vertical coma and the spherical aberration (SA) at the 4.0 mm and 6.0 mm zone of the TG-PRK plus ACXL group significantly decreased at the last follow-up visit (all p < 0.05). The declines of the total corneal aberrations, the corneal LOAs, the corneal HOAs and the vertical coma at the 4.0 mm and 6.0 mm zone of the TG-PRK plus ACXL group were significantly decreased at the last follow-up visit (all p < 0.05). The declines of the total corneal aberrations, the corneal LOAs, the corneal HOAs and the vertical coma at the 4.0 mm and 6.0 mm zone of the TG-PRK plus ACXL group were significantly higher than those in the ACXL alone group (p < 0.001).

Conclusion: Compared with ACXL alone, combined TG-PRK with ACXL procedure had a significantly higher reduction in the corneal HOAs and better

CDVA, while providing a similar long-term stability and safety. For progressive keratoconus patients with adequate corneal thickness, the combined procedure might be a recommended treatment option.

KEYWORDS

topography guided photorefractive keratectomy, accelerated corneal cross-linking, progressive keratoconus, higher order aberrations, vertical coma

1 Introduction

Keratoconus is recognized as a progressive, bilateral, and often asymmetric corneal condition influenced by both genetic (family history) and environmental factors, such as eye rubbing and nocturnal ocular compression (1). It is now acknowledged that inflammatory factors play a role in the disease (2-4). Characteristically, keratoconus leads to thinning and steepening of the paracentral cornea, which results in progressive irregular astigmatism and may lead to irreversible visual loss (1). Corneal cross-linking (CXL) can increase the mechanical rigidity of cornea, and it is proved to be an effective method to halt the progression of the keratoconus (5). In the standard protocol (also known as "Dresden protocol"), the corneal epithelium was removed and the central cornea infiltrated with 0.1% riboflavin solution was exposed to the Ultraviolet A light at 3 mW/cm² for 30 min (6). Accelerated corneal cross-linking (ACXL) with much higher irradiation were proposed thereafter, and the protocols included 9 mW/cm² for 10 min, 18 mW/cm² for 5 min, and so on (7). Compared with the standard CXL, these protocols offered the similar efficacy but a shorter operative duration (8). However, in general, CXL is not considered as a refractive procedure and may not contribute to the visual improvement.

The earliest attempt to solve the puzzle was the combination of the sequential treatment of topography-guided photorefractive keratectomy (TG-PRK) and CXL (9). An optimized protocol of simultaneous TG-PRK and ACXL was proposed by Krueger and Kanellopoulos thereafter, which was named "Athens protocol" (10). Since then, different protocols on different platforms had been proposed, demonstrating efficacy in delaying disease progression and improving the visual acuity (11–14). In comparison with CXL alone, the combined procedure demonstrated the significantly improved vision, with the similar results regarding postoperative stability and complications (15–18).

Theoretically, the TG-PRK procedure regularized the central cornea of the progressive keratoconus patients, leading to less corneal higher order aberrations (HOAs) (19). This might be the critical reason for the greater visual improvement of the combined procedure. However, only a few studies have assessed ocular or corneal aberrations. Iselin et al. reported a significant improvement of the total corneal HOAs, mainly coma-like aberrations, at 12 and 24 months after the combined procedure in comparison to CXL alone (15). However, only a few aberrometric parameters, including the total corneal aberrations, the corneal lower-order aberrations (LOAs), the corneal HOAs and the coma-like aberrations, were involved in the study. Other corneal HOAs associating with the postoperative visual quality of the patients were not analyzed. There is a need for a more comprehensive and detailed analysis of the aberrations. Furthermore,

considering the longitudinal changes of the corneal morphology, the long-term observation is needed.

In this study, we comprehensively compared the long-term outcome of the combined TG-PRK with ACXL surgery and ACXL alone. We focused on the change in the detailed aberrometric values, and hoped to get a comprehensive understanding of the combined procedure.

2 Materials and methods

2.1 Patients and study design

This was a single-center, prospective cohort study. The study was conducted at Peking University Third Hospital. Written consents were obtained before surgery. Peking University Third Hospital Medical Science Research Ethics Committee approved this study according to the Declaration of Helsinki (IRB No.00006761).

Between October 2015 and March 2021, a total of 42 patients (45 eyes) with the progressive keratoconus were enrolled in this study. The diagnosis of keratoconus was based on the slit lamp examination, corneal tomography and pachymetry findings. The keratoconus was further characterized as "progressive" if either of the following criteria was met: (1) an increase of 1D or more in the maximal keratometry of the anterior corneal surface (Kmax) within 12 months; (2) the astigmatism changes of more than 1 D within 12 months; (3) a decrease of $30\,\mu\text{m}$ or more in the thinnest corneal thickness (TCT) (20).

The preoperative corneal thickness of the enrolled patients met the criteria for the combined procedure, ensuring a TCT of more than $450 \,\mu\text{m}$ or a predicted postoperative thickness of stromal bed of more than $350 \,\mu\text{m}$. Exclusion criteria were as follows: (1) Refusal to participate in this study or not available for long-term follow-up; (2) Other types of corneal ectasia, especially the pellucid marginal degeneration; (3) Previous history of corneal surgery, such as keratoplasty and laser vision correction; (4) History of ocular diseases other than keratoconus or ocular trauma; (5) Presence of systemic disease, especially diabetes, autoimmune and infective disease; (6) Pregnant and lactation or planning a pregnancy within 1 year after ACXL.

At the time of cohort entry, patients were stratified according to the preoperative Kmax: (1) Severe subgroup: Kmax values \geq 55D; (2) Mild to moderate subgroup: Kmax values <55 D. Within either subgroup, patients were allocated to the TG-PRK plus ACXL group and the ACXL alone group. The allocation ratio was controlled at 2:1, considering that the study participants would potentially benefit from the combined procedure.

2.2 Clinical examination

All patients underwent a comprehensive ophthalmic examination before surgery. We analyzed the preoperative data and the postoperative measurement data at the last follow-up visit, including demographic data, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction, corneal topography, pachymetry, aberrometry and densitometry. UDVA and CDVA were converted to logMAR for analysis. Besides, the severity of the corneal haze was evaluated by slit-lamp biomicroscopy at the last follow-up visit. It was graded according to the system reported by Hanna et al. (21). The primary outcome was the aberrometry results at the last follow-up visit, and the secondary outcomes were the visual acuity, the refractive results, tomography, pachymetry, densitometry and postoperative complications.

Corneal tomography and pachymetry were measured by Pentacam HR system (Oculus GmbH, Wetzlar, Germany). Parameters including anterior radius of curvature (ARC), posterior radius of curvature (PRC), Belin/Ambrósio total deviation value (BAD-D), index of surface variance (ISV), index of vertical asymmetry (IVA), keratoconus index (KI), center keratoconus index (CKI), index of height asymmetry (IHA) and index of height decentration (IHD) were used to evaluate the severity of keratoconus. Flat keratometry (K1), steep keratometry (K2), Kmax, TCT, central corneal thickness (CCT) and apex thickness (AT) were collected for the longitudinal analysis.

In addition, aberrometric and densitometric values were obtained at each follow-up visit using the Pentacam. In the Pentacam HR system, the corneal wavefront aberrations were reconstructed from the Scheimpflug corneal tomographic data. Aberrations for the entire cornea over the calculation diameter of 2, 4 and 6 mm were analyzed with the Zernike polynomials (22). A refractive index of 1.3375 were used for the computation of the aberrations. The data included the root mean square (RMS) of the total corneal aberrations, the RMS of the corneal LOAs, the RMS of the corneal HOAs, horizontal coma, vertical coma, horizontal trefoil, oblique trefoil and spherical aberration (SA). The densitometry values for total corneal thickness within the central 0-2 mm cornea and the intermediate 2–6 mm zone were expressed in grayscale units (23).

2.3 Surgical procedure

At the initiation of the procedure, the central 9mm of the epithelium was mechanically debrided after the cornea was exposed to 20% ethylic alcohol for 20s using a well. All procedures were performed by the same surgeon (YGC).

2.3.1 Topography guided photorefractive keratectomy surgical procedure

Prior to the surgery, a high-quality scan was obtained using Topolyzer Vario (Alcon, United States). The magnitude and the axis of the preoperative corneal astigmatism was automatically calculated based on the Topolyzer topographic results. Given that the goal of the excimer laser surface ablation was to minimize corneal irregularities rather than correct refractive errors, the sphere correction was set to "0" in the preoperative refractive planning. The size of the ablation optical zone was set at 5.0, 5.5, 6.0 or 6.5 mm, and the maximum ablation depth was limited to 50 μ m. The cylinder correction was customized for each patient, not exceeding the stromal ablation depth limit. The magnitude of the cylinder correction ranged from 0 to 2.75D, and the axis was consistent with the axis of the preoperative corneal astigmatism. All TG-PRK procedures were performed on the WaveLight EX500 (Alcon, United States) excimer laser. The static cyclotorsion and the chord mu, which is a proxy for the kappa angle, were automatically compensated for (24). Mitomycin C was not used during the surgery. The main parameters of the TG-PRK procedure were presented in Table 1.

2.3.2 Accelerated corneal cross-linking procedure

Immediately after the TG-PRK procedure or the epithelial debridement, ACXL was performed using a uniform protocol. Before irradiation, the anterior surface of the deepithelialized cornea was thoroughly soaked in 0.1% riboflavin (Peschke M[®], Peschke Meditrade GmbH) for 10 min. Afterward, the central 8 mm of the cornea was exposed to the 365 nm ultraviolet-A light. Both groups had underwent the ACXL at 30 mW/cm² for 4 min. At the same time, we continued to apply 0.1% riboflavin drops to the cornea to maintain the riboflavin saturation.

After the surgery, a bandage contact lens was applied. The lens was removed after 7 days when re-epithelialization was completed. All patients were treated topically with 0.5% levofloxacin (Santen Pharmaceuticals, Osaka, Japan) 4 times a day until complete corneal epithelialization. Fluorometholone 0.1% (Santen Pharmaceutical, Osaka, Japan) was applied 4 times a day with weekly tapering for 4 weeks. To reduce the effect of the intraocular pressure on the cornea morphology and prevent the steroid-induced ocular hypertension in the short-term after surgery, all patients were instructed to apply 2% carteolol hydrochloride (Otsuka Pharmaceutical, Shanghai, China) 2 times a day for 4 weeks.

2.4 Astigmatic vector analysis

Vector analysis of the manifest astigmatism was performed with the assistance of the ASSORT Group Analysis Calculator (ASSORT Pty. Ltd.) based on the Alpins method (25). All manifest refraction data was converted from the spectacle plane to the corneal plane

TABLE 1 Procedure-related parameters.

	Mean <u>+</u> SD/ Median (IQR)*
Optical zone diameter (mm)	5.50 (0.50)
Transition zone diameter (mm)	1.25 (0.00)
Total ablation zone (mm)	8.50 (0.50)
Maximum ablation depth (µm)	40.91 ± 7.59
Central ablation depth (µm)	29.62 ± 7.50
Predicted postoperative residual stromal bed thickness (µm)	374.93±27.01
Attempted sphere (D)	0.00 (0.00)
Attempted cylinder (D)	-1.22 ± 0.79

SD, standard deviation; IQR, interquartile range. *Normally distributed parameters were expressed as mean \pm SD, while non-normally distributed parameters were expressed as the median with IQR.

using a vertex distance of 12 mm. We calculated the following vectors: surgically induced astigmatism (SIA), which represents the astigmatism achieved by the surgery; target-induced astigmatism (TIA), which represents the astigmatic correction that was attempted; angle of error (AE), which represents the angle between the axis of the SIA and the axis of the TIA; difference vector (DV), which represents the vectorial difference between the TIA and SIA vectors; correction Index (CI), which represents the SIA divided by the TIA.

2.5 Sample size calculation

We aimed to detect the differences between the postoperative corneal HOAs of the TG-PRK plus ACXL group and the ACXL alone group. Based on the previous clinical trial, the mean postoperative corneal HOAs of the CXL alone group was $0.73\pm0.36\,\mu$ m. A decline in the corneal HOAs of 0.33 μ m was expected in the TG-PRK plus CXL group (15). The sample size ratio between the two groups was 2:1. A power of 80% was set and the alpha error was set as 0.05. With these settings, we estimated that we needed a total of at least 45 eyes, 30 eyes in the TG-PRK plus ACXL group and 15 eyes in the ACXL alone group. Sample size calculation was performed with G*power software, V.3.1.9.

2.6 Statistical analysis

Data analysis was performed with SPSS 24.0 (IBM SPSS Statistics 24.0, United States). Data were graphed using Microsoft Excel 2019 (Microsoft Corporation, Redmond, WA, United States). Normal distribution was tested with the Shapiro-Wilk test and QQ plots. Normally distributed data was expressed as mean ± standard deviation, while non-normally distributed continuous data was presented as median (interquartile range). Among the long-term follow-up, no patients were lost and no data were missing. In each group, the comparison between preoperative and postoperative parameters were performed with paired t-test. Student's t-test was applied for comparison between different groups. All the continuous variables involved in the comparison were showed to be normally distributed. Categorical variables (e.g., gender) were expressed as number (percentage), and Chi-square test was used for analysis. A p value less than 0.05 was considered significant. To further assess the long-term outcomes, we performed the analysis in severity subgroups. Given the limited statistical power, subgroup analysis was considered as exploratory only. The results of the subgroup analysis were presented in Supplementary Table S1 for the readers' further reference.

3 Results

There were 28 patients (30 eyes) in the TG-PRK plus ACXL group and 14 patients (15 eyes) in the ACXL alone group. Two patients underwent bilateral TG-PRK plus ACXL and 1 patient underwent bilateral ACXL alone. The mean duration of the follow-up was 44 ± 10.18 months (ranged from 31 to 65 months). Demographic and preoperative data of both groups were presented in Table 2. There were no significant differences in the baseline characteristics between the two groups (all p > 0.05).

Table 3 showed the visual acuity, refractive outcomes, topography and pachymetry at the last follow-up visit. Compared with preoperative values, the CDVA at the last follow-up visit improved significantly to 0.14 ± 0.16 in the TG-PRK plus ACXL group (p=0.006), while no significant improvement was found in the CDVA of the ACXL alone group (p=0.432). No significant improvements in the UDVA and the manifest refraction were found in either group at the last follow-up visit.

Compared with the preoperative value, the Kmax of both groups significantly decreased at the last follow-up visit (p < 0.05). K1 and K2 decreased significantly in the TG-PRK plus ACXL group (p < 0.05), and remained stable at the ACXL alone group (p > 0.05). Corneal thickness parameters, including CCT, AT and TCT, decreased significantly in the TG-PRK plus ACXL group (all p < 0.001), while remained stable in the ACXL alone group (p > 0.05).

For both groups, Figure 1 illustrated the Snellen line changes in CDVA from baseline to the postoperative follow-ups. At the time of the last follow-up visit, 9 eyes (30.0%) of the TG-PRK plus ACXL group and 1 eye (6.7%) of the ACXL alone group gained 2 or more lines.

The vector analysis outcomes of the TG-PRK plus ACXL group at the last follow-up visit were shown in Supplementary Figure S1. The mean TIA of the TG-PRK plus ACXL group was $0.74 \times 173^{\circ}$, while the mean SIA was $0.18 \times 105^{\circ}$ (Supplementary Figures S1C,D). The mean DV was $0.87 \times 177^{\circ}$ (Supplementary Figure S1E). However, there was no significant correlation between TIA and SIA (p > 0.05; Supplementary Figure S1A). The AE and the CI had a large variation (Supplementary Figures S1B,F).

Representative preoperative and postoperative topography maps of the combined TG-PRK with ACXL procedure obtained by Pentacam were shown in Figure 2. Significant topographic improvement could be seen 4 years postoperatively.

Representative preoperative and postoperative topography maps of the ACXL alone obtained by Pentacam were shown in Figure 3. No significant changes were observed. Table 4 presented the preoperative and postoperative aberrometric values in various calculation zones for both groups. Compared with the preoperative value, the total corneal aberrations, the corneal LOAs, the corneal HOAs, the vertical coma and the SA at each corneal zone of the TG-PRK plus ACXL group significantly decreased at the last follow-up visit (all p < 0.05). The horizontal coma at the corneal zone of 6.0 mm, the oblique trefoil at the corneal zone of 4.0 mm and 6.0 mm also significantly decreased (p < 0.05). In the ACXL alone group, the total corneal aberrations and the corneal LOAs of the 4.0 mm and 6.0 mm zone significantly decreased at the last follow-up visit (p < 0.05). In addition, the corneal HOAs and the vertical coma of the 2.0 mm and 4.0 mm zone significantly decreased (p < 0.05).

Table 5 showed the changes of the densitometric values at the last follow-up visit. For both groups, the densitometric values within the central 0–2 and 2–6 mm significantly increased at the last follow-up visit (p < 0.001).

Table 6 compared the changes in the topography, aberrometric and the densitometric values between the two groups at the last follow-up visit. The analysis showed that compared with the ACXL alone group, the Kmax of the TG-PRK plus ACXL group showed a

TABLE 2 Patient demographic and preoperative data.

Characteristics	TG-PRK plus AC>	(L group (<i>n</i> = 30)	ACXL alone group (<i>n</i> = 15)		P value	
	Preoperative	Range	Preoperative	Range		
Gender (m/f)	19 (63.3%) / 11 (36.7%)		11 (73.3%)/4 (26.7%)		0.502	
Laterality (OD/OS)	10 (33.3%) / 20 (66.7%)		6 (40.0%)/9 (60.0%)		0.660	
Age at operation (years)	23±7.73	9-45	23±5.98	14-37	0.816	
Postoperative follow-up (months)	46 ± 10.06	31-65	41±9.95	32-60	0.132	
Visual acuity		·		· · · · · · · · · · · · · · · · · · ·		
UCVA (logMAR)	0.75 ± 0.37	0.10-1.70	0.88 ± 0.36	0.22-1.70	0.291	
CDVA (logMAR)	0.24 ± 0.17	0.00-0.70	0.20 ± 0.15	0.00-0.52	0.480	
		Refractive resu	lts			
Manifest Sphere (D)	-4.96 ± 2.75	-1.2511.25	-6.23 ± 3.39	-2.0012.25	0.183	
Manifest Cylinder (D)	-3.86 ± 1.74	-1.508.00	-4.10 ± 2.52	0.0010.00	0.708	
MRSE (D)	-6.89 ± 2.97	-2.0014.25	-8.28 ± 3.79	-3.0014.50	0.183	
		Topography				
ARC (mm)	6.68 ± 0.44	5.96-7.64	6.86 ± 0.43	6.06-7.74	0.219	
PRC (mm)	5.07 ± 0.44	4.24-5.93	5.16 ± 0.44	4.38-6.24	0.503	
K1 (D)	45.74 ± 2.62	41.4-51.5	44.71 ± 2.04	41.4-48.2	0.193	
K2 (D)	50.02 ± 3.35	43.9-56.8	49.15 ± 2.76	44.8-55.9	0.387	
Kmax (D)	55.74 ± 4.90	47.2-64.5	54.83 ± 4.38	45.8-62.4	0.544	
BAD-D	7.73 ± 2.43	3.63-12.75	7.23 ± 2.72	3.29-13.65	0.531	
		Pachymetry				
CCT (µm)	492.10 ± 22.00	450-556	487.87 ± 20.42	456-526	0.537	
AT (μm)	483.97 ± 22.10	443-552	480.47 ± 20.16	454-527	0.609	
TCT (µm)	476.17 ± 23.79	436-547	473.60 ± 21.26	441-516	0.726	
Severity indices						
ISV	80.03 ± 25.02	37-130	77.80 ± 31.79	34-136	0.798	
IVA	0.81 ± 0.32	0.28-1.44	0.79 ± 0.45	0.24-1.69	0.848	
КІ	1.20 ± 0.07	1.09–1.34	1.19 ± 0.11	1.03-1.44	0.711	
СКІ	1.07 ± 0.04	0.99–1.16	1.06 ± 0.04	1.01-1.13	0.756	
IHA	32.16 ± 27.96	0.8-110.0	35.00 ± 30.59	3.0-122.0	0.757	
IHD	0.114 ± 0.047	0.034-0.193	0.103 ± 0.061	0.021-0.222	0.527	

TG-PRK, topography-guided photorefractive keratectomy; ACXL, accelerated corneal cross-linking; m, male; f, female; OD, right eye; OS, left eye; UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; MRSE, refractive spherical equivalent; ARC, anterior radius of curvature; PRC, posterior radius of curvature; K1, flat keratometry; K2, steep keratometry; Kmax, the maximal keratometry of the anterior corneal surface; BAD-D, Belin/Ambrósio total deviation value; CCT, central corneal thickness; AT, apex thickness; TCT, thinnest corneal thickness; ISV, index of surface variance; IVA, index of vertical asymmetry; K1, keratoconus index; CKI, center keratoconus index; IHA, index of height asymmetry; IHD, index of height decentration. Data were presented as mean ± standard deviation unless otherwise indicated. A P value of less than 0.05 was considered statistically significant.

	TG-PRK plus ACXL	. group (<i>n</i> = 30)	ACXL alone gr	a sa la sh		
	Last follow-up	<i>p</i> -value ^a	Last follow-up	<i>p</i> -value ^a	p-value ^b	
Visual acutiy and refractive	e results					
UDVA (logMAR)	0.75 ± 0.29	0.948	0.74 ± 0.30	0.062	0.955	
CDVA (logMAR)	0.14 ± 0.16	0.006	0.18 ± 0.13	0.432	0.404	
Manifest Sphere (D)	-4.85 ± 3.11	0.759	-7.12 ± 3.15	0.205	0.035	
Manifest Cylinder (D)	-3.79 ± 2.16	0.794	-4.12 ± 1.63	0.780	0.632	
MRSE (D)	-6.75 ± 3.47	0.745	-9.17 ± 3.25	0.358	0.038	
Topography						
K1 (D)	45.20 ± 2.48	0.001	44.65 ± 1.90	0.750	0.450	
K2 (D)	49.38 ± 3.58	0.010	48.89 ± 2.74	0.373	0.644	
Kmax (D)	52.68 ± 4.96	<0.001	53.87 ± 4.39	0.035	0.435	
Pachymetry						
CCT (µm)	470.50 ± 25.34	<0.001	491.80 ± 26.56	0.199	0.012	
AT (μm)	459.43 ± 22.48	<0.001	481.73 ± 26.43	0.640	0.005	
TCT (µm)	447.37 ± 21.87	<0.001	474.40 ± 27.06	0.742	0.001	

TABLE 3 Visual acuity, refractive outcome, topography and pachymetry at the last follow-up visit in the TG-PRK plus ACXL group and the ACXL alone group.

TG-PRK, topography-guided photorefractive keratectomy; ACXL, accelerated corneal cross-linking; UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; MRSE, refractive spherical equivalent; K1, flat keratometry; K2, steep keratometry; Kmax, the maximal keratometry of the anterior corneal surface; CCT, central corneal thickness; AT, apex thickness; TCT, thinnest corneal thickness. Data were presented as mean ± standard deviation unless otherwise indicated. A P value of less than 0.05 was considered statistically significant. ^aDifferences between preoperative and postoperative values. ^bDifferences between two groups at the last follow-up visit.



greater decline (p=0.008). The declines of the total corneal aberrations, the corneal LOAs, the corneal HOAs and the vertical coma at the 4.0 mm and 6.0 mm zone of the TG-PRK plus ACXL

group were significantly higher than those in the ACXL alone group (p < 0.001). The SA at the 2.0 mm and 4.0 mm zone of the TG-PRK plus ACXL group showed a greater decrease, but the changes of SA at



Pentacam Scheimpflug images obtained from the left eye of a 16-year-old male patient who had undergone the combined topography guided photorefractive keratectomy with accelerated corneal cross-linking procedure. Preoperative tangential curvature map showed the keratoconus with the inferiorly decentred cone (middle). Postoperative tangential curvature map at 4-year follow-up visit revealed the flattening and better centration of the cone (left side). The corresponding tangential curvature difference map demonstrated the annular ablation zone located in the paracentral cornea (right side). The laser ablation flattened the cone apex and steepened the superior central cornea by flattening the surrounded section, thus regularizing the morphology of the central cornea.

the 6.0 mm zone showed no significant difference between the two groups (p > 0.05). The changes in the densitometric values at the last follow-up visit showed no significant differences between two groups (p > 0.05).

In the TG-PRK plus ACXL group, 14 eyes (46.7%) were categorized into the severe subgroup, and 16 eyes (53.3%) were categorized into the mild to moderate subgroup. In the ACXL alone group, 7 eyes (46.7%) were categorized into the severe subgroup, and 8 eyes (53.3%) were categorized into the mild to moderate subgroup. Subgroup analysis showed the significant difference between the mean change of the Kmax of the TG-PRK plus ACXL group and the ACXL alone group in the severe subgroup (p = 0.024), while no significant difference was found in the mean change of the topographic parameters in the mild to moderate subgroup (all p > 0.05). In both subgroups, the changes of the total corneal aberrations, the corneal LOAs, the corneal HOAs and the vertical coma at the 4.0 mm and the 6.0 mm zone differed significantly between the two procedures (all p < 0.05). No significant difference was found in the changes of the densitometric values in either subgroup (all p > 0.05; Supplementary Table S1).

Central corneal haze had been noted in 20 eyes (66.7%) of the TG-PRK plus ACXL group and 9 eyes (60.0%) of the ACXL alone group postoperatively. The haze had regressed completely in all patients at the last follow-up visit, but the severity and duration of the

haze differed between the two groups. In the ACXL alone group, the haze ranged from 0.5 to 1 in all patients, and regressed within 1 year postoperatively. However, in the TG-PRK plus ACXL group, 3 eyes had exhibited a haze score of 2. The haze score ranged from 0.5 to 1 in other eyes. Besides, the haze could be observed in 6 eyes (20.0%) of the TG-PRK plus ACXL group at the 1-year postoperative follow-up visit, of which the haze regressed completely by 2 years postoperatively. No other severe complications were observed.

4 Discussion

This study prospectively compared the long-term outcome, especially the corneal aberrometric results of combined TG-PRK with ACXL and ACXL alone. The results of this study suggested that the combined procedure had the better long-term outcome and could be beneficial for the improvement in the corneal HOAs.

CXL was first reported by Wollensak et al. (6), and its treatment plan was named as the Dresden protocol. It is considered as the standard treatment for progressive keratoconus due to the long-term efficacy and safety (26, 27). More recently, different protocols have been proposed. The accelerated protocol shortened the operation time by increasing the irradiation intensity (5). It had been proved to have similar efficacy and safety compared with the standard protocol (28).



Pentacam Scheimpflug images obtained from the left eye of a 25-year-old male patient who had undergone the accelerated corneal cross-linking alone. Preoperative tangential curvature map showed the keratoconus with the inferiorly decentred cone (middle). No significant alteration in corneal morphology was observed at 4-year postoperative tangential curvature map (left side) and the corresponding tangential curvature difference map (right side).

In our study, we applied the ACXL at $30 \,\text{mW/cm}^2$ for 4 min. It maintained the adequate total dosage while improving the operating efficiency, therefore minimized the risk for complications.

For keratoconus patients, the progressive protrusion of the cornea caused the increased corneal irregularity, which led to the high myopia and irregular astigmatism (29). The stiffening effect generated by the CXL would confer a certain degree of the corneal curvature regularization. However, in fact, most patients who underwent CXL still complained about the blurred vision due to the significant residual corneal irregularity (19). Accordingly, the concept of "CXL plus" was proposed, referring to the combining refractive procedures that aims to further regularize the cornea (30). Kanellopoulos et al. first described a sequential treatment combining TG-PRK and CXL (9). Thereafter, Krueger and Kanellopoulos proposed a simultaneous protocol combining TG-PRK and the high-influence CXL, which was named "Athens protocol." It is still the classical approach for corneal regularization in keratoconus (10, 11). As an effective treatment option, the Athens protocol showed the long-term safety, stability as well as the long-lasting improvement of the visual function (31). The conventional Athens protocol planned to correct 70% of the cylinder and less than 70% of the sphere, so as not to exceed the maximal stromal removal of 50 µm. Besides, the optical zone was limited to 5.5 mm (11, 32). However, in our study, only partial cylinder was actively corrected. The optical zone was appropriately expanded under the limit of the maximal stromal removal. We expected to get a greater improvement of the visual quality while preserving as much corneal tissue as possible. In previous comparative studies, the UDVA of the patients who underwent the Athens protocol procedure markedly improved in the long-term follow-up (31). Besides, compared with the CXL alone, combined TG-PRK with CXL showed more significant improvement in the UDVA (15-18). However, our study found no significant improvement in UDVA in either group. This was likely due to the fact that the corneal ablation was performed in our study with no sphere correction and partial cylinder correction, therefore the pre-existing refractive error remained mostly unchanged after surgery in both groups. It is worth pointing out that although the combined procedure was performed with a certain cylinder correction, our study found no significant difference in the refractive values before and after the surgery. On the one hand, the limited sample size of our study might mask the minor discrepancy in the preoperative and postoperative cylinder values. On the other hand, the corneal morphology of the keratoconus patients inevitably altered during the long-term follow-up, which made it difficult to ensure the stability of the laser ablation. The vector analysis also showed the inaccuracy of the refractive correction after the long-term follow-up.

The results of our study demonstrated the long-term efficacy of TG-PRK procedure in improving the CDVA. CDVA improved significantly in the TG-PRK plus ACXL group, whereas it remained unchanged in the majority of the patients of the ACXL alone group. This matched the results of preceding studies (15–18).

				5 1	5		
	TG-PRK plus ACXL group (<i>n</i> = 30)			ACX	ACXL alone group (<i>n</i> = 15)		
	Preoperative	Last follow- up	<i>p</i> -value	Preoperative	Last follow- up	<i>p</i> -value	
2.0 mm zone							
RMS total (µm)	0.77 ± 0.33	0.53 ± 0.32	<0.001	0.79 ± 0.36	0.70 ± 0.32	0.130	
RMS LOAs (µm)	0.75 ± 0.32	0.52 ± 0.32	<0.001	0.77 ± 0.36	0.69 ± 0.32	0.139	
RMS HOAs (µm)	0.16 ± 0.08	0.08 ± 0.06	<0.001	0.15 ± 0.08	0.14 ± 0.07	0.020	
Coma 0 (µm)	0.01 ± 0.07	0.00 ± 0.04	0.242	0.00 ± 0.06	-0.01 ± 0.07	0.060	
Coma 90 (µm)	-0.14 ± 0.07	-0.04 ± 0.06	<0.001	-0.13 ± 0.08	-0.11 ± 0.08	0.003	
Trefoil 0 (µm)	0.01 ± 0.03	0.00 ± 0.02	0.084	0.00 ± 0.03	0.01 ± 0.02	0.126	
Trefoil 30 (µm)	0.00 ± 0.02	0.01 ± 0.03	0.086	0.02 ± 0.04	0.02 ± 0.04	0.956	
Spherical aberration	-0.01 ± 0.02	0.00 ± 0.01	0.002	-0.01 ± 0.01	-0.01 ± 0.01	0.546	
4.0 mm zone							
RMS total (µm)	3.94 ± 1.59	2.40 ± 1.36	<0.001	3.82 ± 1.57	3.46 ± 1.58	0.005	
RMS LOAs (µm)	3.82 ± 1.54	2.34 ± 1.33	<0.001	3.70 ± 1.51	3.35 ± 1.51	0.009	
RMS HOAs (µm)	0.99 ± 0.44	0.48 ± 0.33	<0.001	0.94 ± 0.50	0.87 ± 0.49	0.029	
Coma 0 (µm)	0.08 ± 0.42	0.01 ± 0.26	0.094	0.02 ± 0.39	-0.02 ± 0.44	0.134	
Coma 90 (µm)	-0.82 ± 0.40	-0.24 ± 0.35	<0.001	-0.74 ± 0.49	-0.64 ± 0.50	0.005	
Trefoil 0 (µm)	0.05 ± 0.17	-0.01 ± 0.12	0.102	-0.01 ± 0.14	0.04 ± 0.12	0.102	
Trefoil 30 (µm)	-0.04 ± 0.14	0.04 ± 0.16	0.049	0.08 ± 0.24	0.10 ± 0.20	0.851	
Spherical aberration	-0.17 ± 0.19	-0.06 ± 0.16	0.001	-0.15 ± 0.15	-0.13 ± 0.14	0.400	
6.0 mm zone							
RMS total (µm)	9.82 ± 3.85	5.95 ± 3.31	<0.001	9.26 ± 4.04	8.54 ± 4.19	0.001	
RMS LOAs (µm)	9.56 ± 3.75	5.77 ± 3.23	<0.001	9.00 ± 3.87	8.28 ± 4.03	0.001	
RMS HOAs (µm)	2.21 ± 0.89	1.41 ± 0.79	<0.001	2.15 ± 1.20	2.05 ± 1.22	0.209	
Coma 0 (µm)	0.22 ± 0.89	0.07 ± 0.73	0.017	0.05 ± 1.00	-0.02 ± 1.14	0.357	
Coma 90 (µm)	-1.65 ± 0.79	-0.79 ± 0.72	<0.001	-1.49 ± 1.16	-1.30 ± 1.21	0.093	
Trefoil 0 (µm)	0.12 ± 0.36	0.02 ± 0.28	0.177	-0.01 ± 0.23	0.06 ± 0.26	0.199	
Trefoil 30 (µm)	-0.14 ± 0.38	0.02 ± 0.33	0.039	0.10 ± 0.50	0.14 ± 0.42	0.735	
	0.14 ± 0.50	0.02 ± 0.003	0.055	0.10 ± 0.50	0.11 ± 0.12	017 00	

TABLE 4 Pre- and postoperative comparison of aberrometric data for the TG-PRK plus ACXL group and the ACXL alone group at the last follow-up visit.

TG-PRK, topography-guided photorefractive keratectomy; ACXL, accelerated corneal cross-linking; RMS, root mean square; LOAs, the lower-order aberrations; HOAs, the higher-order aberrations. Data were presented as mean ± standard deviation unless otherwise indicated. A *P* value of less than 0.05 was considered statistically significant.

TABLE 5 Pre- and postoperative comparison of densitometric data for the TG-PRK plus ACXL group and the ACXL alone group at the last follow-up visit.

	TG-PRK plus ACXL group (<i>n</i> = 30)		ACXL alone group (<i>n</i> = 15)			
	Preoperative	Last follow-up	<i>p</i> -value	Preoperative	Last follow-up	<i>p</i> -value
0.0–2.0 mm	12.08 ± 1.03	16.20 ± 2.86	< 0.001	12.41 ± 1.16	15.99 ± 2.13	<0.001
2.0-6.0 mm	10.80 ± 0.99	13.91 ± 2.22	< 0.001	11.08 ± 1.00	14.33 ± 1.85	<0.001

TG-PRK, topography-guided photorefractive keratectomy; ACXL, accelerated corneal cross-linking. Data were presented as mean \pm standard deviation unless otherwise indicated. A *P* value of less than 0.05 was considered statistically significant.

Compared with the ACXL alone, the combined procedure further regularized the anterior corneal surface, therefore eliminated most of the irregular astigmatism unable to be fully corrected by the spectacles.

The laser ablation caused a significant decrease in the pachymetry of the TG-PRK plus ACXL group. Despite this, in our study, the combined protocol showed the long-term stability. We found a significant decrease in K1, K2 and Kmax of the TG-PRK plus ACXL group after the long-term follow-up. The Kmax of the ACXL alone group also showed a significant decrease, but the reduction was significantly lower than the TG-PRK plus ACXL group. On the one hand, the TG-PRK procedure remodeled the anterior surface of cornea, and therefore led to the decrease in keratometric values (19). A previous study showed that the improvement of the keratometric

10.3389/fmed.2024.1420264

	TG-PRK plus ACXL group (n = 30)	ACXL alone group (n = 15)	<i>p</i> -value			
Topography						
ΔK1 (D)	0.53 ± 0.78	0.07 ± 0.79	0.067			
ΔK2 (D)	0.65 ± 1.29	0.26 ± 1.10	0.325			
ΔKmax (D)	3.06 ± 2.68	0.95 ± 1.58	0.008			
2.0 mm aberrometric value	es					
Δ RMS total (µm)	0.24 ± 0.26	0.08 ± 0.20	0.051			
Δ RMS LOAs (µm)	0.22 ± 0.26	0.08 ± 0.20	0.070			
Δ RMS HOAs (µm)	0.09 ± 0.06	0.01 ± 0.02	<0.001			
ΔComa 0 (µm)	0.01 ± 0.05	0.01 ± 0.02	0.841			
ΔComa 90 (µm)	-0.11 ± 0.06	-0.02 ± 0.02	<0.001			
Δ Trefoil 0 (µm)	0.01 ± 0.04	-0.01 ± 0.02	0.020			
Δ Trefoil 30 (µm)	-0.01 ± 0.04	0.00 ± 0.04	0.358			
Δ Spherical aberration	-0.01 ± 0.02	0.00 ± 0.01	0.017			
4.0 mm aberrometric value	es					
ΔRMS total (µm)	1.54 ± 1.09	0.36 ± 0.43	< 0.001			
Δ RMS LOAs (µm)	1.47 ± 1.06	0.35 ± 0.45	< 0.001			
Δ RMS HOAs (µm)	0.50 ± 0.28	0.08 ± 0.12	<0.001			
$\Delta Coma 0 (\mu m)$	0.08 ± 0.24	0.04 ± 0.10	0.539			
$\Delta Coma 90 (\mu m)$	-0.58 ± 0.33	-0.10 ± 0.12	< 0.001			
Δ Trefoil 0 (µm)	0.06 ± 0.20	-0.06 ± 0.12	0.044			
Δ Trefoil 30 (µm)	-0.08 ± 0.21	-0.01 ± 0.26	0.356			
Δ Spherical aberration	-0.11 ± 0.16	-0.02 ± 0.08	0.012			
6.0 mm aberrometric value	es					
ΔRMS total (µm)	3.87 ± 2.46	0.72 ± 0.66	< 0.001			
Δ RMS LOAs (µm)	3.80 ± 2.43	0.72 ± 0.65	< 0.001			
Δ RMS HOAs (µm)	0.80 ± 0.50	0.10 ± 0.30	< 0.001			
ΔComa 0 (µm)	0.15 ± 0.33	0.06 ± 0.25	0.357			
ΔComa 90 (µm)	-0.86 ± 0.56	-0.19 ± 0.41	< 0.001			
Δ Trefoil 0 (µm)	0.10 ± 0.41	-0.08 ± 0.22	0.117			
Δ Trefoil 30 (µm)	-0.17 ± 0.42	-0.04 ± 0.42	0.337			
Δ Spherical aberration	-0.16 ± 0.36	-0.03 ± 0.22	0.204			
Densitometric values						
$\Delta 0.0-2.0\mathrm{mm}$	-4.12 ± 2.87	-3.58 ± 2.32	0.531			
Δ2.0–6.0 mm	-3.11 ± 2.13	-3.25 ± 2.11	0.832			

TABLE 6 Comparison of the changes in topography, aberrometric and densitometric data between the TG-PRK plus ACXL group and the ACXL alone group at the last follow-up visit.

TG-PRK, topography-guided photorefractive keratectomy; ACXL, accelerated corneal crosslinking; K1, flat keratometry; K2, steep keratometry; Kmax, the maximal keratometry of the anterior corneal surface; RMS, root mean square; LOAs, the lower-order aberrations; HOAs, the higher-order aberrations. Data were presented as mean ± standard deviation unless otherwise indicated. A P value of less than 0.05 was considered statistically significant.

values after the combined procedure was maintained in the long-term follow-up (31). On the other hand, the stiffening effect of the CXL had been reported to cause the flattening of the cone apex and the steepening of the part of the cornea symmetrically opposite the cone

(33). Several studies had compared the reduction in keratometric values of the TG-PRK plus CXL with CXL alone. Among them, some studies showed that the combining treatment was advantageous in the improvement of the keratometric values (15, 16), while the other showed no significant difference (17). However, a latest meta-analysis clearly showed that compared with CXL alone, TG-PRK plus CXL showed a significant reduction in keratometric values such as Kmax (18). Our findings supported this result, and further showed that the differences in the changes of the Kmax mainly occurred in the severe subgroup. This might suggest that compared with mild to moderate keratoconus patients, those with the severe keratoconus might benefit more from the TG-PRK plus ACXL procedure. Moreover, the better results in the keratometric values of the combined treatment also corresponded to the significantly greater improvement in CDVA and aberrometric values.

Our study revealed the long-term changes in the aberrometric values of two treatments. In our study, the total corneal aberrations and the corneal LOAs significantly decreased at the 4.0 mm and 6.0 mm corneal zone of the both groups. The measurement of the corneal HOAs showed that the total corneal HOAs and the vertical coma at each corneal zone improved significantly in the TG-PRK plus ACXL group at the last follow-up visit. In the ACXL alone group, the total corneal HOAs and the vertical coma of the 2 mm and 4 mm zone improved significantly. Besides, the improvements in the total corneal aberrations, the corneal LOAs, the corneal HOAs and the vertical coma of the TG-PRK plus ACXL group were significantly higher than the ACXL alone group. It had been well-established that the total corneal aberrations, the corneal LOAs, the corneal HOAs and the coma-like aberrations significantly increased in the keratoconus eyes, and the change of the aberrations occurred predominantly in the anterior corneal surface (34, 35). Besides, the higher-order aberrations of the keratoconus eyes mainly consisted of the coma-like aberrations, which was caused by the misalignment of the corneal apex and the other optic elements (34). Previous studies had demonstrated that CXL might potentially improve the corneal HOAs and the total coma of the anterior cornea (36, 37). The TG-PRK procedure further regularized the morphology of the anterior corneal surface and decreased the corneal asymmetry, and therefore effectively reduced the aberrometric values, especially the coma-like aberrations (38). Iselin et al. reported that compared with the CXL alone, the combined procedure showed a significant decrease of the total corneal aberrations, the corneal LOAs, the corneal HOAs and the coma-like aberrations at 12 months of follow-up (15). Alessio et al. reported that the total corneal aberrations and the coma-like aberrations significantly decreased after 24 months of follow up in the TG-PRK plus CXL group (16). The results of our study matched these findings, and further illustrated that the improvement of the comalike aberrations was mainly due to the improvement of the vertical coma. This might be attributed to the decrease of the vertical asymmetry of the cornea. Moreover, in both subgroups, the changes in the total corneal HOAs and the vertical coma of the TG-PRK plus ACXL group were significantly higher than the ACXL alone group. From the perspective of the improvement in the corneal HOAs, patients within either subgroup could benefit from the combined procedure. In our study, the SA showed a significant decrease in the TG-PRK plus ACXL group, and the significant difference with the ACXL alone group in the postoperative SA change was only detected in the 2 mm and 4 mm zone. Our previous study revealed a similar result (39). A few other studies supported our observations, showing a significant decrease in the SA after TG-PRK combined with ACXL (14, 40). The decrease of the SA over a certain range might correspond to the different software with ablation algorithms, while the improvement of the SA over a wider range might be caused by the flattening of the central cornea.

Our study demonstrated the long-term safety of the two treatments. Transient corneal haze is a common complication of the CXL, and it usually resolves within 1 year (41). In the combined TG-PRK with CXL surgery, the ablation of the Bowman layer leads to a greater effect of the CXL treatment on the anterior corneal stromal (17, 42). Besides, the PRK procedure involves the disruption of the basement membrane and underlying stroma, and the subsequent inflammatory response is also the crucial factor that leads to corneal opacity (43). The previous studies had reported a high incidence of the corneal haze after the combined TG-PRK with CXL surgery (44, 45). Few studies had compared the occurrence of the corneal haze between the two treatments. Alessio et al. reported that 7 of 17 eyes in the TG-PRK plus CXL group and 4 of 17 eyes in the CXL alone group had developed central corneal haze during 24 months of follow-up (16). Singal et al. showed that compared with CXL alone, the corneal haze of the eyes in the TG-PRK plus CXL group persisted for a longer duration (46). In concordance, in the TG-PRK plus ACXL group of our study, the corneal haze occurred with the higher severity and the slower regression. Even so, the incidence of the corneal haze was similar in both groups, and the corneal haze had regressed completely by the last follow-up visit. Therefore, in the long term, the safety of both treatments was similar.

The severity of the corneal haze can be quantitatively assessed by corneal densitometry analysis with the Scheimpflug technology (47). Studies evaluating the long-term densitometry changes after the CXL were scarce, and the existing studies had showed the inconsistent results (48, 49). Iselin et al. had reported an equivalent rise in densitometry values of the TG-PRK plus CXL and CXL alone at 12 and 24 months postoperatively (15). Our study provided a similar long-term outcome. At the last follow-up visit, both groups in our study showed an increase in the densitometry values of the central 2 mm zone and the adjacent 2.0 to 6.0 mm ring. No significant differences were found between the changes of the values of both groups, indicating the similar long-term safety. There were many factors that can influence the long-term outcome of the corneal densitometry, such as different surgical protocols, age of the patients and the severity of keratoconus (47). Hence, more quantitative evaluation is required to reveal the natural history of the corneal haze after the two treatments.

In this study, mitomycin C was not used during the TG-PRK procedure. It had been demonstrated that the adjunctive use of mitomycin C can effectively prevent the occurrence of the post-PRK corneal haze (43). However, the use of the mitomycin C in the combined CXL procedures remained controversial (50). Despite the fact that the mitomycin C was used in the conventional Athens protocol, it might increase the incidence of the corneal haze after the CXL (51). Kymionis et al. found that the CXL procedure itself could inhibit the regeneration of the keratocyte in the corneal anterior stromal (52). Therefore, additional use of the mitomycin C was not necessary (11).

There were also some limitations in our study. Firstly, the main outcome of our study was the aberrometric values provided by the Pentacam. The primary data Pentacam obtains is the corneal elevation, according to which corneal aberrations are calculated indirectly. The aberrometric values differed significantly between most aberrometers (53). Therefore, more comprehensive quantitative and instrumental studies are required to verify our results. Secondly, the corneal wavefront aberration parameters could not fully describe the visual quality of the patients. The aberrations of the entire eye and a subjective visual quality questionnaire should be included in future studies to enrich the analysis. Thirdly, owing to the limited sample size, the subgroup analysis might be underpowered to detect the significant differences between groups. Fourthly, due to the design of our study, patients involved in our study were relatively mild in the severity of keratoconus and had adequate corneal thickness. For patients with more severe keratoconus, the long-term outcomes of the CXL were not within the scope of our study. The optimal treatment for these patients needs further investigation. Fifthly, due to the limited sample size, both eyes of some patients were included in this study. The between-eye correlation may affect our results.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The study was approved by the Peking University Third Hospital Medical Science Research Ethics Committee and conducted in compliance with the principles of the Declaration of Helsinki (IRB No.00006761). Informed consent was obtained from the participants or their legal guardians (if the participant was underage).

Author contributions

ZD: Investigation, Writing – original draft. ZL: Writing – review & editing. YZ: Writing – review & editing. YY: Writing – review & editing. YL: Writing – review & editing. YW: Writing – review & editing. SY: Writing – review & editing. YC: Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Acknowledgments

We thank the participants of the study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

1. Bui AD, Truong A, Pasricha ND, Indaram M. Keratoconus diagnosis and treatment: recent advances and future directions. *Clin Ophthalmol.* (2023) 17:2705–18. doi: 10.2147/OPTH.S392665

2. Galvis V, Tello A, Barrera R, Niño CA. Inflammation in keratoconus. *Cornea*. (2015) 34:e22–3. doi: 10.1097/ICO.00000000000499

3. Elbeyli A, Kurtul BE. Systemic immune-inflammation index, neutrophil-tolymphocyte ratio, and platelet-to-lymphocyte ratio levels are associated with keratoconus. *Indian J Ophthalmol.* (2021) 69:1725–9. doi: 10.4103/ijo.IJO_3011_20

4. Loh IP, Sherwin T. Is keratoconus an inflammatory disease? The implication of inflammatory pathways. *Ocul Immunol Inflamm.* (2022) 30:246–55. doi: 10.1080/09273948.2020.1780271

5. Angelo L, Gokul Boptom A, McGhee C, Ziaei M. Corneal crosslinking: present and future. *Asia Pac J Ophthalmol (Phila).* (2022) 11:441–52. doi: 10.1097/APO.00000000000557

6. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. *Am J Ophthalmol.* (2003) 135:620–7. doi: 10.1016/s0002-9394(02)02220-1

 Chan C. Corneal cross-linking for keratoconus: current knowledge and practice and future trends. Asia Pac J Ophthalmol (Phila). (2020) 9:557–64. doi: 10.1097/ APO.00000000000335

 Shajari M, Kolb CM, Agha B, Steinwender G, Müller M, Herrmann E, et al. Comparison of standard and accelerated corneal cross-linking for the treatment of keratoconus: a meta-analysis. *Acta Ophthalmol.* (2019) 97:e22–35. doi: 10.1111/ aos.13814

9. Kanellopoulos AJ, Binder PS. Collagen cross-linking (CCL) with sequential topography-guided PRK: a temporizing alternative for keratoconus to penetrating keratoplasty. *Cornea.* (2007) 26:891–5. doi: 10.1097/ICO.0b013e318074e424

10. Krueger RR, Kanellopoulos AJ. Stability of simultaneous topography-guided photorefractive keratectomy and riboflavin/UVA cross-linking for progressive keratoconus: case reports. *J Refract Surg.* (2010) 26:S827–32. doi: 10.3928/1081597X-20100921-11

11. Moshirfar M, Rognon GT, Olson N, Kay W, Sperry RA, Ha S, et al. Merging PRK and collagen crosslinking: an analysis of literature and a guide to prevalent protocols. *Cornea*. (2024) 2024:536. doi: 10.1097/ICO.000000000003536

12. Grentzelos MA, Liakopoulos DA, Kankariya VP, Siganos CS, Tsilimbaris MK, Pallikaris IG, et al. Three-year results of simultaneous Transepithelial phototherapeutic keratectomy and conventional photorefractive keratectomy (Cretan protocol plus) followed by corneal crosslinking for keratoconus. *Cornea*. (2023) 42:680–6. doi: 10.1097/ ICO.000000000003168

13. Yousif MO, Elkitkat RS, Edrees ES, Alaarag NA. Introducing a revised tissue saving protocol for combined topography-guided photorefractive keratectomy and crosslinking in Keratoconic corneas. *Cornea*. (2023) 42:755–65. doi: 10.1097/ ICO.000000000003225

14. Jain R, Shuaib Y, Mohan N, Mittal V. Outcomes of topography-guided PRK/CXL in keratoconus using the NIDEK CXIII system-"Bharat protocol" (pilot study). *Indian J Ophthalmol.* (2023) 71:3203–9. doi: 10.4103/IJO.IJO_295_23

15. Iselin KC, Baenninger PB, Bachmann LM, Bochmann F, Thiel MA, Kaufmann C. Changes in higher order aberrations after central corneal regularization - a comparative two-year analysis of a semi-automated topography-guided photorefractive keratectomy combined with corneal cross-linking. *Eye Vis (Lond).* (2020) 7:10. doi: 10.1186/ s40662-020-00179-2

16. Alessio G, L'Abbate M, Sborgia C, La Tegola MG. Photorefractive keratectomy followed by cross-linking versus cross-linking alone for management of progressive keratoconus: two-year follow-up. *Am J Ophthalmol.* (2013) 155:54–65.e1. doi: 10.1016/j. ajo.2012.07.004

17. Kontadakis GA, Kankariya VP, Tsoulnaras K, Pallikaris AI, Plaka A, Kymionis GD. Long-term comparison of simultaneous topography-guided photorefractive keratectomy

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2024.1420264/ full#supplementary-material

followed by corneal cross-linking versus corneal cross-linking alone. *Ophthalmology*. (2016) 123:974–83. doi: 10.1016/j.ophtha.2016.01.010

18. Achiron A, Yahalomi T, Knyazer B, Hecht I, Elbaz U, Spierer O, et al. Efficacy comparison of combining cross-linking and refractive laser ablation in progressive keratoconus: a network meta-analysis of short-term outcomes and systemic review. *Can J Ophthalmol.* (2024) 1:17. doi: 10.1016/j.jcjo.2024.02.017

19. Kankariya VP, Dube AB, Grentzelos MA, Kontadakis GA, Diakonis VF, Petrelli M, et al. Corneal cross-linking (CXL) combined with refractive surgery for the comprehensive management of keratoconus: CXL plus. *Indian J Ophthalmol.* (2020) 68:2757–72. doi: 10.4103/ijo.IJO_1841_20

20. Gomes JA, Tan D, Rapuano CJ, Belin MW, Ambrósio R, Guell JL, et al. Global consensus on keratoconus and ectatic diseases. *Cornea*. (2015) 34:359–69. doi: 10.1097/ICO.000000000000408

21. Hanna KD, Pouliquen YM, Waring GO, Savoldelli M, Fantes F, Thompson KP. Corneal wound healing in monkeys after repeated excimer laser photorefractive keratectomy. *Arch Ophthalmol.* (1992) 110:1286–91. doi: 10.1001/archopht.1992.01080210104035

22. Thibos LN, Applegate RA, Schwiegerling JT, Webb R. Standards for reporting the optical aberrations of eyes. *J Refract Surg.* (2002) 18:S652–60. doi: 10.3928/1081-597X-20020901-30

23. ND S, Rozema JJ, Jongenelen S, Ruiz Hidalgo I, Zakaria N, Tassignon MJ. Normative values for corneal densitometry analysis by Scheimpflug optical assessment. *Invest Ophthalmol Vis Sci.* (2014) 55:162–8. doi: 10.1167/iovs.13-13236

24. Chang DH, Waring GO. The subject-fixated coaxially sighted corneal light reflex: a clinical marker for centration of refractive treatments and devices. *Am J Ophthalmol.* (2014) 158:863–874.e2. doi: 10.1016/j.ajo.2014.06.028

25. Alpins N. Astigmatism analysis by the Alpins method. J Cataract Refract Surg. (2001) 27:31–49. doi: 10.1016/s0886-3350(00)00798-7

26. Meyer JJ, Jordan CA, Patel DV, Gokul A, Dean SJ, Ahmed S, et al. Five-year results of a prospective, randomised, contralateral eye trial of corneal crosslinking for keratoconus. *Clin Experiment Ophthalmol.* (2021) 49:542–9. doi: 10.1111/ceo.13959

27. Mazzotta C, Traversi C, Baiocchi S, Bagaglia S, Caporossi O, Villano A, et al. Corneal collagen cross-linking with riboflavin and ultraviolet a light for pediatric keratoconus: ten-year results. *Cornea*. (2018) 37:560–6. doi: 10.1097/ICO.00000000001505

28. Kobashi H, Tsubota K. Accelerated versus standard corneal cross-linking for progressive keratoconus: a Meta-analysis of randomized controlled trials. *Cornea*. (2020) 39:172–80. doi: 10.1097/ICO.00000000002092

29. Santodomingo-Rubido J, Carracedo G, Suzaki A, Villa-Collar C, Vincent SJ, Wolffsohn JS. Keratoconus: an updated review. *Cont Lens Anterior Eye.* (2022) 45:101559. doi: 10.1016/j.clae.2021.101559

30. Kymionis GD. Corneal collagen cross linking - PLUS. Open Ophthalmol J. (2011) 5:10. doi: 10.2174/1874364101105010010

31. Kanellopoulos AJ. Ten-year outcomes of progressive keratoconus management with the Athens protocol (topography-guided partial-refraction PRK combined with CXL). J Refract Surg. (2019) 35:478–83. doi: 10.3928/1081597X-20190627-01

32. Kanellopoulos AJ. Comparison of sequential vs same-day simultaneous collagen cross-linking and topography-guided PRK for treatment of keratoconus. *J Refract Surg.* (2009) 25:S812–8. doi: 10.3928/1081597X-20090813-10

33. Vinciguerra P, Albè E, Trazza S, Rosetta P, Vinciguerra R, Seiler T, et al. Refractive, topographic, tomographic, and aberrometric analysis of keratoconic eyes undergoing corneal cross-linking. *Ophthalmology*. (2009) 116:369–78. doi: 10.1016/j.ophtha.2008.09.048

34. Colak HN, Kantarci FA, Yildirim A, Tatar MG, Goker H, Uslu H, et al. Comparison of corneal topographic measurements and high order aberrations in keratoconus and normal eyes. *Cont Lens Anterior Eye.* (2016) 39:380–4. doi: 10.1016/j. clae.2016.06.005

35. Maeda N, Fujikado T, Kuroda T, Mihashi T, Hirohara Y, Nishida K, et al. Wavefront aberrations measured with Hartmann-shack sensor in patients with keratoconus. *Ophthalmology*. (2002) 109:1996–2003. doi: 10.1016/s0161-6420(02)01279-4

36. Kirgiz A, Eliacik M, Yildirim Y. Different accelerated corneal collagen crosslinking treatment modalities in progressive keratoconus. *Eye Vis (Lond)*. (2019) 6:16. doi: 10.1186/s40662-019-0141-6

37. Greenstein SA, Fry KL, Hersh MJ, Hersh PS. Higher-order aberrations after corneal collagen crosslinking for keratoconus and corneal ectasia. *J Cataract Refract Surg.* (2012) 38:292–302. doi: 10.1016/j.jcrs.2011.08.041

38. Kanellopoulos AJ, Asimellis G. Comparison of Placido disc and Scheimpflug image-derived topography-guided excimer laser surface normalization combined with higher fluence CXL: the Athens protocol, in progressive keratoconus. *Clin Ophthalmol.* (2013) 7:1385–96. doi: 10.2147/OPTH.S44745

39. Zhang Y, Chen Y. Topography-guided corneal surface laser ablation combined with simultaneous accelerated corneal collagen cross-linking for treatment of keratoconus. *BMC Ophthalmol.* (2021) 21:286. doi: 10.1186/s12886-021-02042-x

40. Shetty R, Ahuja P, D'Souza S, Khamar P, Paritekar P, Dadachanji Z, et al. Simultaneous topography-guided PRK/CXL versus topography-assisted PTK/CXL: 1-year prospective outcomes in Keratoconic eyes. *J Refract Surg.* (2021) 37:562–9. doi: 10.3928/1081597X-20210609-01

41. Wu D, Lim DK, Lim BXH, Wong N, Hafezi F, Manotosh R, et al. Corneal crosslinking: the evolution of treatment for corneal diseases. *Front Pharmacol.* (2021) 12:686630. doi: 10.3389/fphar.2021.686630

42. Alessio G, L'Abbate M, Furino C, Sborgia C, La Tegola MG. Confocal microscopy analysis of corneal changes after photorefractive keratectomy plus cross-linking for keratoconus: 4-year follow-up. *Am J Ophthalmol.* (2014) 158:476–84.e1. doi: 10.1016/j. ajo.2014.05.024

43. Moshirfar M, Wang Q, Theis J, Porter KC, Stoakes IM, Payne CJ, et al. Management of Corneal Haze after Photorefractive Keratectomy. *Ophthalmol Ther.* (2023) 12:2841–62. doi: 10.1007/s40123-023-00782-1

44. Iqbal M, Elmassry A, Tawfik A, Elgharieb ME, Al Nahrawy ED, Osama M, et al. Evaluation of the effectiveness of cross-linking combined with photorefractive keratectomy for treatment of keratoconus. *Cornea*. (2018) 37:1143–50. doi: 10.1097/ ICO.000000000001663

45. Moraes RLB, Ghanem RC, Ghanem VC, Santhiago MR. Haze and visual acuity loss after sequential photorefractive keratectomy and corneal cross-linking for keratoconus. *J Refract Surg.* (2019) 35:109–14. doi: 10.3928/1081597X-20190114-01

46. Singal N, Ong Tone S, Stein R, Bujak MC, Chan CC, Chew HF, et al. Comparison of accelerated CXL alone, accelerated CXL-ICRS, and accelerated CXL-TG-PRK in progressive keratoconus and other corneal ectasias. *J Cataract Refract Surg.* (2020) 46:276–86. doi: 10.1097/j.jcrs.000000000000049

47. Chan TCY, Chan JCK, Wang YM, Rapuano CJ. Survival analysis of corneal densitometry after collagen cross-linking for progressive keratoconus. *Cornea*. (2018) 37:1449–56. doi: 10.1097/ICO.00000000001686

48. Alnawaiseh M, Rosentreter A, Eveslage M, Eter N, Zumhagen L. Changes in corneal transparency after cross-linking for progressive keratoconus: long-term followup. J Refract Surg. (2015) 31:614–8. doi: 10.3928/1081597X-20150820-07

49. Nemeth G, Hassan J, Modis L Jr, Hassan Z. Long-term changes in backscattered light measurements in keratoconus corneas treated with collagen cross-linking. *Curr Eye Res.* (2018) 43:18–26. doi: 10.1080/02713683.2017.1377260

50. Deshmukh R, Ong ZZ, Rampat R, Alió Del Barrio JL, Barua A, Ang M, et al. Management of keratoconus: an updated review. *Front Med (Lausanne)*. (2023) 10:1212314. doi: 10.3389/fmed.2023.1212314

51. Awwad ST, Chacra LM, Helwe C, Dhaini AR, Telvizian T, Torbey J, et al. Mitomycin C application after corneal cross-linking for keratoconus increases stromal haze. *J Refract Surg.* (2021) 37:83–90. doi: 10.3928/1081597X-20201124-01

52. Kymionis GD, Diakonis VF, Kalyvianaki M, Portaliou D, Siganos C, Kozobolis VP, et al. One-year follow-up of corneal confocal microscopy after corneal cross-linking in patients with post laser in situ keratosmileusis ectasia and keratoconus. *Am J Ophthalmol.* (2009) 147:774–778.e1. doi: 10.1016/j.ajo.2008.11.017

53. Piccinini AL, Golan O, Hafezi F, Randleman JB. Higher-order aberration measurements: comparison between Scheimpflug and dual Scheimpflug-Placido technology in normal eyes. *J Cataract Refract Surg.* (2019) 45:490–4. doi: 10.1016/j. jcrs.2018.11.015